1. Home
  2. ENSC vs GDHG Comparison

ENSC vs GDHG Comparison

Compare ENSC & GDHG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ENSC
  • GDHG
  • Stock Information
  • Founded
  • ENSC 2003
  • GDHG 2008
  • Country
  • ENSC United States
  • GDHG China
  • Employees
  • ENSC N/A
  • GDHG N/A
  • Industry
  • ENSC Biotechnology: Pharmaceutical Preparations
  • GDHG Services-Misc. Amusement & Recreation
  • Sector
  • ENSC Health Care
  • GDHG Consumer Discretionary
  • Exchange
  • ENSC Nasdaq
  • GDHG Nasdaq
  • Market Cap
  • ENSC 9.5M
  • GDHG 8.1M
  • IPO Year
  • ENSC N/A
  • GDHG 2023
  • Fundamental
  • Price
  • ENSC $6.07
  • GDHG $1.90
  • Analyst Decision
  • ENSC
  • GDHG
  • Analyst Count
  • ENSC 0
  • GDHG 0
  • Target Price
  • ENSC N/A
  • GDHG N/A
  • AVG Volume (30 Days)
  • ENSC 154.9K
  • GDHG 54.7K
  • Earning Date
  • ENSC 11-12-2024
  • GDHG 02-13-2025
  • Dividend Yield
  • ENSC N/A
  • GDHG N/A
  • EPS Growth
  • ENSC N/A
  • GDHG N/A
  • EPS
  • ENSC N/A
  • GDHG 1.62
  • Revenue
  • ENSC $4,421,404.00
  • GDHG $25,549,903.00
  • Revenue This Year
  • ENSC N/A
  • GDHG N/A
  • Revenue Next Year
  • ENSC N/A
  • GDHG N/A
  • P/E Ratio
  • ENSC N/A
  • GDHG $1.16
  • Revenue Growth
  • ENSC 40.41
  • GDHG N/A
  • 52 Week Low
  • ENSC $2.12
  • GDHG $1.40
  • 52 Week High
  • ENSC $30.90
  • GDHG $68.50
  • Technical
  • Relative Strength Index (RSI)
  • ENSC 42.77
  • GDHG 51.82
  • Support Level
  • ENSC $5.34
  • GDHG $1.43
  • Resistance Level
  • ENSC $8.27
  • GDHG $1.97
  • Average True Range (ATR)
  • ENSC 1.06
  • GDHG 0.21
  • MACD
  • ENSC -0.24
  • GDHG 0.05
  • Stochastic Oscillator
  • ENSC 18.43
  • GDHG 87.04

About ENSC Ensysce Biosciences Inc.

Ensysce Biosciences Inc is a clinical-stage biotech company using its proprietary technology platforms to develop safer prescription drugs. The company is developing a new class of powerful, tamper-proof opioids that prevent both drug abuse and overdoses. Its products are anticipated to provide safer options to treat severe pain and assist in preventing deaths caused by opioid abuse, reducing human and economic costs. The company's current development pipeline includes two new drug platforms: an abuse-resistant opioid prodrug technology, the Trypsin Activated Abuse Protection, or the TAAP platform, and an over-dose protection opioid prodrug technology, the Multi-Pill Abuse Resistant, or the MPAR platform. The Company currently operates in one business segment, which is pharmaceuticals.

About GDHG Golden Heaven Group Holdings Ltd.

Golden Heaven Group Holdings Ltd is an offshore holding company. Through the operating entities in China, It manages and operates six properties consisting of amusement parks, water parks, and complementary recreational facilities. The parks offer a broad selection of exhilarating and recreational experiences, including both thrilling and family-friendly rides, water attractions, gourmet festivals, circus performances, and high-tech facilities. The parks collectively contain nearly 159 rides and attractions. The firm's revenue is generated from selling access to rides and attractions, charging fees for special event rentals, and collecting regular rental payments from commercial tenants.

Share on Social Networks: